About Us

Company Information

Company Profile

Company Name
iXgene Inc.
1-6 Naito-cho, Shinjuku-ku, Tokyo
January 6, 2020
90 million yen
Representative Director
Dr. Toshiharu Furukawa
Main Business
Development of regenerative medicine using genome-edited iPS cells

Our History

November 2018
Basic patent application PCT/JP2018/042629 “Suicide gene therapeutic agent for brain tumors using pluripotent stem cell.”
January 2020
Establishment of iXgene
March 2020
Publication on gene-cell therapy for glioblastoma using suicide gene-transfected iPS cell-derived neural stem cells R. Tamura, Hum. Gene Ther.(2020)
October 2020
Seed round financing completed
March 2021
Patent application PCT/JP2021/13834 ”Therapeutic agent using genome-edited pluripotent stem cell”
December 2022
Series A financing completed
June 2023
Publication on neuroprotective effects of genome-edited iPS cell-derived neural stem cells in traumatic brain injury R. Imai, Stem Cells (2023)
August 2023
Signed a three-way joint research agreement with Sumitomo Pharma and Keio University.